These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9303391)

  • 21. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
    Koyama K; Takahashi M; Oitate M; Nakai N; Takakusa H; Miura S; Okazaki O
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4845-51. PubMed ID: 19687241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
    Takahashi E; Sawabuchi T; Kimoto T; Sakai S; Kido H
    J Dairy Sci; 2019 Nov; 102(11):9559-9569. PubMed ID: 31495632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
    Nicholson KG; Aoki FY; Osterhaus AD; Trottier S; Carewicz O; Mercier CH; Rode A; Kinnersley N; Ward P
    Lancet; 2000 May; 355(9218):1845-50. PubMed ID: 10866439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.
    Lew W; Chen X; Kim CU
    Curr Med Chem; 2000 Jun; 7(6):663-72. PubMed ID: 10702632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereospecific synthesis of a GS 4104 metabolite: determination of absolute stereochemistry and influenza neuraminidase inhibitory activity.
    Lew W; Escarpe PA; Mendel DB; Sweeny DJ; Kim CU
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2811-4. PubMed ID: 10522696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Chugh R; Gupta M; Yeole R; Patel A; Bhatia A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
    Arns S; Tan J; Sun S; Galey A; Zisman N; Ross F; Udechukwu J; Dercho S; Gusti V; Paquette J; Webb M; Bourque E; Withers SG; Liggins R
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2505-9. PubMed ID: 25980910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
    J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
    Ishizuka H; Toyama K; Yoshiba S; Okabe H; Furuie H
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3873-8. PubMed ID: 22526307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oseltamivir: a clinical and pharmacological perspective.
    Doucette KE; Aoki FY
    Expert Opin Pharmacother; 2001 Oct; 2(10):1671-83. PubMed ID: 11825310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuraminidase inhibitors: zanamivir and oseltamivir.
    McNicholl IR; McNicholl JJ
    Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
    Morimoto K; Kishimura K; Nagami T; Kodama N; Ogama Y; Yokoyama M; Toda S; Chiyoda T; Shimada R; Inano A; Kano T; Tamai I; Ogihara T
    J Pharm Sci; 2011 Sep; 100(9):3854-61. PubMed ID: 21607954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.
    Housman ST; Pope JS; Russomanno J; Salerno E; Shore E; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2627-34. PubMed ID: 22330925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.